Gene expression profiles of pretreatment biopsies from dose-dense-docetaxel-treated breast cancers. Homo sapiens

The purpose of this study was to identify molecular markers of pathologic response to neoadjuvant dose-dense docetaxel treatment using gene expression profiling on pretreatment biopsies. Patients with high-risk, operable breast cancer were treated with 75 mg/m2 IV of docetaxel on day 1 of each cycle every 2 weeks x 4 cycles . Tumor tissue from pretreatment biopsies was obtained from 12 patients enrolled in the study. Gene expression profiling were done on serial sections of the biopsies from patients that achieved a pathologic complete response (pCR) and compared to those with residual disease, non-pCR (NR). Overall design: Tumor tissues from pretreatment needle biopsies from patients enrolled in a dose-dense docetaxel clinical trial were laser capture microdissected for RNA extraction and hybridization to Affymetrix microarrays. We analyzed one array (sample A) from duplicate samples from each patient.

本研究旨在通过对治疗前活检标本开展基因表达谱分析（gene expression profiling），鉴定新辅助剂量密集多西他赛治疗的病理应答分子标志物。纳入研究的高危可手术乳腺癌患者接受每2周1个周期、共4个周期的治疗，每个周期第1天静脉输注75 mg/m²多西他赛。本研究从12例入组患者中获取了治疗前活检的肿瘤组织。我们对获得病理完全缓解（pathologic complete response, pCR）患者的活检标本连续切片进行基因表达谱分析，并与存在残留病灶的非病理完全缓解（non-pCR, NR）患者的标本进行对比。试验整体设计如下：对纳入剂量密集多西他赛临床试验的患者的治疗前穿刺活检肿瘤组织进行激光捕获显微切割（laser capture microdissection），以提取RNA并与Affymetrix微阵列进行杂交。本研究对每位患者的重复样本均分析了1张芯片（样本A）。